Bionano Genomics Announces Presentation of OGM Utility Across Key Applications at American Society of Human Genetics (ASHG) Annual Meeting
October 20 2022 - 7:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation in American Society of Human Genetics (ASHG)
Annual Meeting 2022. For the first time, ASHG will feature a
dedicated scientific session on genome mapping technologies, with
researchers highlighting optical genome mapping (OGM) as a
technique that has the potential to revolutionize molecular and
cytogenetic research. A record twenty-four scientific and poster
presentations will cover OGM’s utility in genetic disease research
and other research areas including schizophrenia, ataxia,
constitutional and neurodevelopmental disorders.
ASHG’s Annual Meeting brings together industry, medical, and
academic professionals to discuss advances in clinical genomics and
genetics research. ASHG conference sessions will take
place October 25-29, 2022 in Los Angeles, California.
As part of a hosted CoLab session, Bionano’s chief medical
officer, Alka Chaubey, and Dr. Nikhil Sahajpal, a fellow at
Greenwood Genetic Center, will host a discussion titled “Multi-site
Clinical Study of Optical Genome Mapping and Comprehensive Genome
Analysis of SNVs and SVs Utilizing a Single Software Solution.” In
the session, Dr. Sahajpal will share insights from a large,
multi-site clinical study using OGM for analysis of postnatal
genetic disorders, covering OGM’s utility for detecting pathogenic
SVs. He will also highlight the complementary use of NGS and OGM in
helping to solve undiagnosed cases using software that analyzes OGM
and NGS data at the same time. The presentation will take
place Wednesday, October 26, from 10:00-10:30 AM
PDT in the CoLab Theatre 3 room.
A scientific session that was created by conference organizers
to highlight the genome mapping method will be moderated by Dr.
Anwar Iqbal, University of Rochester Medical Center, and
co-moderated by Dr. Sahajpal. Titled “Genome Mapping Technologies-
Enabling Next-generation Cytogenetics,” the session will feature
Dr. Tuomo Mantere, University of Oulu, Dr. Laila El-Khattabi,
Hôpitaux de Paris – Université de Paris, Dr. Rashmi
Kanagal-Shamanna, MD Anderson Cancer Center, and Dr. Adam Smith,
University Health Network, presenting on their experience using OGM
in the field of molecular cytogenetics, as well as the utilization
and limitations of short- and long-read sequencing to detect SVs.
The session will take place Tuesday, October 25, from 4:30-6:00 PM
PDT in the Petree D, West Building.
In addition, 22 posters featuring results from OGM applications
in cytogenetic research will be presented at the conference. The
full content of the posters will be made available on
the Bionano Genomics website once presented at the
conference.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Session |
Title |
Presenter |
Presented |
Invited Scientific Session |
Genome Mapping Technologies- Enabling Next-generation
Cytogenetics |
Mantere T., El-Khattabi L., Kanagal-Shamanna R., Smith A. |
October 25, 20224:30-6:30 PM PDTPetree D, West Building |
Hosted CoLab Session |
Multi-site Clinical Study of Optical Genome Mapping and
Comprehensive Genome Analysis of SNVs and SVs Using a Single
Software Solution |
Chaubey A., Sahajpal N. |
October 26, 202210-10:30 AM PDTCoLab Theatre 3 |
Poster Number |
Title |
Lead Author/Affiliation |
|
Wednesday, October 26 3:00-4:45 PM PDT |
|
PB1102 |
Filling gaps in whole genome analysis in hematology: A chance for
optical mapping and long-read NGS |
Savara J. Palacky University |
PB1169 |
Next generation SP DNA sample prep and DLS labeling readies optical
genome mapping workflows for adoption at scale |
Sadowski H. Bionano Genomics |
PB2245 |
A combination of exome sequencing and optical genome mapping
unveils a dual molecular diagnosis in a case with an unknown
neurodevelopmental disorder |
Acharya A. Columbia University |
PB2261 |
B-allele frequency-based approach to detecting absence of
heterozygosity using optical genome mapping |
Raksi A.Bionano Genomics |
PB2270 |
Clinical utility of parental testing for the reclassification of
likely pathogenic and uncertain copy number and sequence variants
in a pediatric neurodevelopmental disorders cohort |
Bilancia C.Bionano Laboratories |
PB2334 |
Optical genome mapping identified a likely pathogenic POLR3B
variant in an undiagnosed male with ataxia, hypotonia, and
cerebellar atrophy |
Ortega A.Bionano Laboratories |
PB2336 |
Optical genome mapping improves clinical interpretation of
constitutional copy number gains |
Raca G.Children’s Hospital, Los Angeles |
PB2346 |
Statistical method for detection of uniparental disomy using SNP
microarray or NGS technologies |
Roytman M.Bionano Genomics |
PB2356 |
Unmasking of a chromothripsis event using the integrated approach
of chromosomal microarray analysis (CMA) and optical genome mapping
(OGM) |
Loddo S.Bambino Gesù Childrens' Hospital |
PB2375 |
Atypical Prader-Willi and Angelman syndrome deletion: Importance of
parent of origin detection |
Al-Sweel N.Bionano Genomics |
|
Thursday, October 27 3:00-4:45 PM PDT |
|
PB1264 |
An unprecedented level of complexity in the
schizophrenia-associated 3q29 region of the human genome with
unique segments that increase the risk for non-allelic homologous
recombination |
Yilmaz F. The Jackson Laboratory for Genomic Medicine |
PB1900 |
Leveraging orthogonal sequencing and optical mapping technologies
for the precision diagnosis of neurodevelopmental disorders in a
Middle Eastern family-based cohort |
Siddig Z.Sidra Medicine |
PB2094 |
Improving rare conditions diagnostic rates by standardizing
practice and offering preclinical testing |
Delot E.Children’s National/George Washington
University |
PB2119 |
Recurrent constitutional chromosome 5 inversion |
Doco-Fenz M.Service de génétique, REIMS, France |
PB2248 |
A multiomics approach to resolving small supernumerary marker
chromosomes |
Grochowski C.Baylor College of Medicine |
PB2252 |
A novel FAME1 repeat configuration in a European family identified
using a combined genomics approach |
Maroilley T.University of Calgary |
PB2333 |
Optical genome mapping and whole genome sequencing in a case of
multiple chromosomal rearrangements |
Levy J.AP-HP Paris |
PB2335 |
Optical genome mapping identifies double parental paracentric
inversions as risk factor for atypical monocentric recombinant
chromosomes in offspring |
Kuentz P.CHU Besancon |
PB2778 |
De novo assembled and phased human genomes from Persian Arab trios
show divergent and novel sequence versus CHM13 and GRCh38,
providing valuable population specific reference genomes for Middle
Eastern region |
Ghorbani M.Weill-Cornell Medicine |
PB2932 |
Cell manufacturing genome integrity analysis by optical genome
mapping |
Pang A.Bionano Genomics |
PB3154 |
Structural and copy number variant detection, filtering,
annotation, and classification by optical genome mapping in
constitutional disorders |
Clifford B.Bionano Genomics |
|
Friday, October 28 10:30-12:00 PM PDT |
|
PB414 |
The use of optical genome mapping in genetically unsolved
neurodevelopmental disorders |
Schrauwen I. Columbia University |
“We are thrilled to see the scientific and research committees
of the ASHG conference recognize the significance of genome mapping
techniques, such as OGM, being utilized for the assessment of
structural variations. Additionally, we are pleased to see 14
scientific poster presentations from leading research institutions
across the globe, demonstrating OGM’s potential for cutting-edge
research in the human genetics space,” commented Erik Holmlin,
president and chief executive officer of Bionano. “Bionano will
also share new data from our collaboration with Hamilton and the
Long String VANTAGE automation system. The data shows this workflow
may significantly reduce time-to-results, reduce hands-on-time and
improve OGM performance by standardizing the process of UHMW DNA
isolation, and we look forward to demonstrations at the
conference.”
More details on the conference can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome
analysis solutions that can enable researchers and clinicians to
reveal answers to challenging questions in biology and medicine.
The Company’s mission is to transform the way the world sees the
genome through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen,
Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information,
visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “potential,” “will,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the ability and utility of OGM to complement next generation
sequencing (NGS), OGM’s utility in the research of
structural variants in genetic diseases and other research areas
including schizophrenia, ataxia, and constitutional and
neurodevelopmental disorders, and the ability of the Long String
VANTAGE system to reliably and consistently isolate high quality
and sufficient quantity of UHMW DNA for use with OGM . Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of the COVID-19 pandemic
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
failure OGM to achieve useful complementarity with NGS; failure of
OGM to be adopted for the research of structural variants in
genetic diseases and other research areas including schizophrenia,
ataxia, and constitutional and neurodevelopmental disorders; the
ability of our OGM solutions to offer the anticipated benefits for
and contributions to the areas of research reported in the
presentations given and posters made available at the ASHG Annual
Meeting 2022; future study results contradicting the results
reported in the presentations given and posters made available at
the ASHG Annual Meeting 2022; the ability of the Long String
VANTAGE system to reliably and consistently isolate high quality
and sufficient quantity of UHMW DNA for use with OGM; changes in
our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024